Vitrolife AB (publ) (VITR.ST) fair value

ACCE thesis

Vitrolife makes intraocular lenses, IVF culture media and embryo-culture and imaging tools for fertility clinics, and its Stockholm-listed shares carry a forward P/E of 21.4 on a 59.2% gross margin and a 23.1% operating margin. Those margins are the core of the case: the consumables and implants that clinics reorder every cycle, and the lenses that get implanted once and then sit in patients for life, give it recurring, high-margin revenue that few medtech peers match. Revenue is currently shrinking, down 1.6%, so the question for a PM is whether that softness is cyclical in fertility volumes or a sign that the company's growth engine has stalled. The reported ROE of -46.5% is a distortion from a balance sheet that has absorbed large write-downs, and it should not be read as operating losses given the healthy operating margin. At 13.9 billion SEK market cap, with no index membership, the name sits outside most mainstream allocation models, which can mean the valuation reflects the revenue decline more than the franchise quality. Worth a deeper look on whether IVF demand and lens market share have bottomed.